The Fosun-backed eye disease treatment developer has filed for a $100m initial public offering, having raised over $250m in funding in the past two years.
Gyroscope Therapeutics, a UK-based developer of treatments for retinal diseases which counts diversified conglomerate Fosun as an investor, has filed for an initial public offering in the United States.
The company has set a placeholder target of $100m and intends to float on the Nasdaq Global Select Market. Morgan Stanley, Goldman Sachs and Citigroup are joint book-running managers for the IPO.
Gyroscope is developing gene therapies for the treatment of eye diseases that cause vision loss or blindness. It…
